comparemela.com

Latest Breaking News On - Cerevel therapeutics company profile - Page 6 : comparemela.com

Cerevel Therapeutics (NASDAQ:CERE) Shares Gap Down to $30.90

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) shares gapped down before the market opened on Wednesday . The stock had previously closed at $30.90, but opened at $28.85. Cerevel Therapeutics shares last traded at $29.70, with a volume of 306,874 shares traded. Analyst Ratings Changes Several research analysts have commented on the company. Wells […]

Ceon-anthony-coles
Morgan-stanley
Camden-capital
Wells-fargo-company
Hermes-inc
Securities-exchange-commission
Cerevel-therapeutics-company-profile
Cerevel-therapeutics-holdings-inc
Nasdaq
Perceptive-advisors
Fund-management-co
Jpmorgan-chase-co

Cerevel Therapeutics (NASDAQ:CERE) Stock Price Up 7%

Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) rose 7% during trading on Monday . The stock traded as high as $31.25 and last traded at $31.06. Approximately 383,386 shares changed hands during trading, a decline of 36% from the average daily volume of 594,443 shares. The stock had previously closed at $29.04. […]

Ceon-anthony-coles
Morgan-stanley
Cerevel-therapeutics-company-profile
Perceptive-advisors
Berenberg-bank
Barclays-plc
Cerevel-therapeutics-holdings-inc
Jpmorgan-chase-co
Vanguard-group-inc
Wells-fargo-company
Nasdaq
Cerevel-therapeutics-holdings

Cerevel Therapeutics (NASDAQ:CERE) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Cerevel Therapeutics (NASDAQ:CERE – Get Rating) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $45.00 price objective on the biotechnology company’s stock. CERE has been the subject of several other reports. Mizuho lowered their price objective on Cerevel […]

Hong-kong
Canada
Ceon-anthony-coles
Elequin-securities
Cerevel-therapeutics-holdings-inc
High-net-worth-advisory-group
Centaurus-financial-inc
Cantor-fitzgerald
Cerevel-therapeutics-company-profile
Wells-fargo-company
Royal-bank
Hong-kong-ltd

Cerevel Therapeutics (NASDAQ:CERE) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Cerevel Therapeutics (NASDAQ:CERE – Get Rating) in a research note released on Monday, Benzinga reports. They currently have a $45.00 target price on the biotechnology company’s stock. A number of other research analysts have also recently commented on CERE. Wells Fargo & Company cut shares of […]

Ceon-anthony-coles
Morgan-stanley
Cerevel-therapeutics-company-profile
Cantor-fitzgerald
Cerevel-therapeutics-holdings-inc
Prudential-financial-inc
Berenberg-bank
Metlife-investment-management
Wells-fargo-company
Cerevel-therapeutics
Get-rating
Moderate-buy

FY2023 EPS Estimates for Cerevel Therapeutics Holdings, Inc. Decreased by Cantor Fitzgerald (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) – Cantor Fitzgerald cut their FY2023 earnings per share estimates for Cerevel Therapeutics in a report issued on Thursday, February 23rd. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will post earnings of ($2.78) per share for the year, down from their prior forecast […]

Florida
United-states
Mizuho
Sakhalinskaya-oblast
Russia
Canada
Ceon-anthony-coles
Morgan-stanley
Board-of-administration-florida-retirement-system
Cerevel-therapeutics-holdings-inc
Nasdaq
Nisa-investment-advisors

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.